Keywords: hycamtin, value, nsclc, smithkline, beecham, topoisomerase, inhibitor

Hycamtin Of Value In NSCLC

Article | 30 May 1997

SmithKline Beecham's topoisomerase I inhibitor Hycamtin (topotecanhydrochloride) may be a promising new treatment option for advanced squamous cell lung cancer, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Hycamtin

Topotecan Hydrochloride

Go to drug listing